ECCO News

  • 2019 MASTER COVER ECCO News 1
    Issue 1/2019
  • 2018 nr1 Cover ECCO NewsCover 1 2018
    Issue 1/2018
  • 2018 Nr2 Cover ECCO News
    Issue 2/2018
  • 2018 Nr3 Cover ECCO News
    Issue 3/2018
  • 2018 Nr 4 Cover ECCO News
    Issue 4/2018
  • 2017 Nr1 Cover ECCO News
    Issue 1/2017
  • 2017 Nr2 Cover ECCO News
    Issue 2/2017
  • 2017 Nr3 Cover ECCO News
    Issue 3/2017
  • cover ECCO 042017
    Issue 4/2017
  • 2016 Nr1 Cover ECCO News
    Issue 1/2016
  • 2016 Nr2 Cover ECCO News
    Issue 2/2016
  • 2016 Nr3 Cover ECCO News
    Issue 3/2016
  • 2016 Nr4 Cover ECCO News
    Issue 4/2016
  • 2015 Nr1 Cover ECCO News
    Issue 1/2015
  • 2015 Nr2 Cover ECCO News
    Issue 2/2015
  • 2015 Nr3 Cover ECCO News
    Issue 3/2015
  • 2015 Nr4 Cover ECCO News
    Issue 4/2015
  • 2014 Nr1 Cover ECCO News
    Issue 1/2014
  • 2014 Nr2 Cover ECCO News
    Issue 2/2014
  • 2014 Nr3 Cover ECCO News
    Issue 3/2014
  • 2014 Nr4 Cover ECCO News
    Issue 4/2014
  • 2013 Nr1 Cover ECCO News
    Issue 1/2013
  • 2013 Nr2 Cover ECCO News
    Issue 2/2013
  • 2013 Nr3 Cover ECCO News
    Issue 3/2013
  • 2013 Nr4 Cover ECCO News
    Issue 4/2013
  • 2012 Nr1 Cover ECCO News
    Issue 1/2012
  • 2012 Nr2 Cover ECCO News
    Issue 2/2012
  • 2012 Nr3 Cover ECCO News
    Issue 3/2012
  • 2012 Nr4 Cover ECCO News
    Issue 4/2012
  • 2011 Nr1 Cover ECCO News
    Issue 1/2011
  • 2011 Nr2 Cover ECCO News
    Issue 2/2011
  • 2011 Nr3 Cover ECCO News
    Issue 3/2011
  • 2011 Nr4 Cover ECCO News
    Issue 4/2011
  • 2010 Nr1 Cover ECCO News
    Issue 1/2010
  • 2010 Nr2 Cover ECCO News
    Issue 2/2010
  • 2010 Nr3 Cover ECCO News
    Issue 3/2010
  • 2010 Nr4 Cover ECCO News
    Issue 4/2010
  • 2009 Nr1 Cover ECCO News
    Issue 1/2009
  • 2010 Nr2 Cover ECCO News
    Issue 2/2009
  • 2010 Nr3 Cover ECCO News
    Issue 3/2009
  • 2009 Nr4 Cover ECCO News
    Issue 4/2009
  • 2008 Nr1 Cover ECCO News
    Issue 1/2008
  • 2008 Nr2 Cover ECCO News
    Issue 2/2008
  • 2008 Nr3 Cover ECCO News
    Issue 3/2008
  • 2008 Nr4 Cover ECCO News
    Issue 4/2008
  • 2007 Nr1 Cover ECCO News
    Issue 1/2007
  • 2007 Nr2 Cover ECCO News
    Issue 2/2007
  • 2007 Nr3 Cover ECCO News
    Issue 3/2007
  • 2007 Nr4 Cover ECCO News
    Issue 4/2007

ECCO News keeps ECCO Members up-to-date on what is going on within the organisation and reports on IBD activities taking place within Europe. Since Spring 2006, ECCO News has maintained the flow of information between Members of the organisation. 

ECCO News is an important part of the European Crohn’s and Colitis Organisation’s ambition to create a European standard of IBD care and to promote knowledge and research in the field of IBD. ECCO Members automatically receive this publication four times a year. 

Editor

 

Associate Editors

Willem BemelmanWillem Bemelman
© ECCO
                  Nuha Yassin v3Nuha Yassin
© ECCO
Ignacio Catalán Serra 2019Ignacio Catalán-Serra
© Ignacio Catalán-Serra

Latest ECCO News Content


30April2019

ECCO Country Member Profiles: Hungary

Karoly Palatkak and Tamas Molnar, ECCO National Representatives, Hungary

Hungary

  Hungary

Name of group: Hungarian Colon Section
Number of active members: 200
Number of meetings per year:
President and Secretary: Karoly Palatka (president), Klaudia Farkas (secretary)
National Representatives: Tamas Molnar, Karoly Palatka
Joined ECCO in: 2004
Incidence of IBD in the country (if available): 10/100,000

Posted in ECCO News, Volume 14, Issue 1, ECCO Country Member Profiles

30April2019

New JCC feature: Podcasts

Tim Raine, JCC Associate Editor

Tim Raine wrc 2016
Tim Raine 
© ECCO

We are excited to announce this new feature to support readers of the Journal of Crohn’s and Colitis (JCC). Since January, key papers accepted for publication in the journal are being accompanied by a short (5-7 minute) audio recording, made available from the Journal homepage.

Posted in ECCO News, Volume 14, Issue 1, ECCO'19

30April2019

UR-CARE Training Centre at ECCO'19

MASTER ECCO UR CARE No ECCO

Report on the main feedback and questions from the delegates

 

At the 14th Congress of ECCO, the UR-CARE Team received positive feedback from delegates who tried UR-CARE at the UR-CARE Training Centre. Most delegates were very satisfied with the ease of use of the platform and pleasantly surprised that it was free for physicians. Having a standardised platform among the different centres was also very welcomed. People were impressed by the possibility of creating personalised reports of their patients and of having access to a statistical module with the use of desired filters (a timesaving and major asset compared to Access or Excel databases).

Posted in ECCO News, Volume 14, Issue 1, ECCO'19, Congress News, UR-CARE News

30April2019

Y-ECCO/ClinCom call for Y-ECCO Small Research Survey Proposals

Gianluca Pellino & Mark Samaan, Y-ECCO Members

Gianluca Pellino 2019Gianluca Pellino 
© ECCO
Mark Samaan 2019Mark Samaan 
© ECCO

The call for research proposals returns with opportunities for Y-ECCO Members to propose and perform a brief, focused research project with ClinCom/Y-ECCO guidance and ECCO support.

Posted in ECCO News, Volume 14, Issue 1, ClinCom, Y-ECCO

30April2019

Y-ECCO Interview Corner: Tine Jess

Charlotte Hedin, Y-ECCO Member

Charlotte HedinCharlotte Hedin
© ECCO

Our interviewee for this Issue is the current Director of the Center for Clinical Research and Prevention at Bispebjerg and Frederiksberg Hospital in Copenhagen, Denmark. She started her medical training at Herlev University Hospital in Copenhagen, but early in her career the lure of research called and she embarked on a career in epidemiology with a particular focus on IBD and cancer risk. To date she has more than 130 publications listed on PubMed, of which many are highly cited and over 70 are first or last author contributions. She has received many awards for her research and is frequently invited to present her data at international meetings and congresses. Professor Tine Jess, welcome to the Interview Corner.

 

Posted in ECCO News, Volume 14, Issue 1, Committee News, Y-ECCO

30April2019

Y-ECCO Literature Review: Aravind Gokul Tamilarasan

Aravind Gokul Tamilarasan

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in Inflammatory Bowel Disease

Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B

Aliment Pharmacol Ther. 2019;49:880–9

Aravind Gokul Tamilarasan
Aravind Gokul Tamilarasan 
© Aravind Gokul Tamilarasan

Introduction

Since the publication of the landmark SONIC trial in 2010 [1], the use of combination biologic–immunomodulator therapy has been considered best standard practice for patients with Inflammatory Bowel Disease (IBD) who have failed topical therapies or immunomodulators (thiopurines or methotrexate). More recently, real-world data from the PANTS (Personalised anti-TNF therapy in Crohn’s Disease) study demonstrated the benefit of combination therapy (particularly for infliximab) in the form of higher week 54 remission rates and prevention of immunogenicity [2]. Notably, the week 54 remission rates were independent of infliximab trough levels or immunogenicity status, suggesting additional benefits apart from improving the pharmacokinetics of infliximab. This study aimed to provide further real-world data on the effect of combination therapy on clinical and pharmacokinetic outcomes.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 14, Issue 1, Y-ECCO

30April2019

Y-ECCO Literature Review: James Gauci

James Gauci

Risankizumab in patients with moderate to severe Crohn's Disease: An open-label extension study

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO

Lancet Gastroenterol Hepatol. 2018;3:671–80. DOI: https://doi.org/10.1016/S2468-1253(18)30233-4   

James Gauci
James Gauci 
© James Gauci

Introduction

Management of Crohn’s Disease involves the suppression of inflammation through administration of immunosuppressive drugs. While conventional therapies such as corticosteroids and thiopurines exert a broad effect on the immune system, the advent of biological agents has allowed for selective targeting of cytokines and integrins.

Unfortunately, a third of patients treated with tumour necrosis factor (TNF) antagonists demonstrate a primary non-response, with another third developing either secondary failure or intolerance. These patients will then have a lower chance of responding to treatment with other TNF antagonists or with the integrin antagonist vedolizumab.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 14, Issue 1, Y-ECCO

30April2019

Y-ECCO Literature Review: Ivan Lyutakov

Ivan Lyutakov

Serum Concentration of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease

Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland L, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS

Clin Gastroenterol Hepatol. 2018 Nov 15. doi:10.1016/j.cgh.2018.11.012    

Ivan Lyutakov
Ivan Lyutakov 
© Ivan Lyutakov

Introduction

Inflammatory Bowel Disease (IBD) comprises a heterogeneous group of chronic inflammatory disorders with two main conditions, Crohn’s Disease (CD) and Ulcerative Colitis (UC) [1]. Bile acid malabsorption (BAM) and bile acid diarrhoea (BAD) have been recognised to be a common cause of chronic diarrhoea, and this recognition has led to the initiation of a search for new screening tests (biomarkers). BAM is one of the mechanisms leading to microscopic colitis, a key factor in the pathogenesis of irritable bowel syndrome-diarrhoea, and molecular mechanisms of BAM are found in IBD patients with or without involvement of the terminal ileum. BAM/BAD is more frequently found in CD than in UC, and the obvious aetiology for BAM in CD is either ileal resection or ileal disease [2]. The pathophysiology of diarrhoea in CD is multifactorial but there are two key factors, colonic water and electrolyte absorption, which can be impaired directly by colonic inflammation or indirectly by increased concentrations of bile acids having secretory effects, referred to as BAD [3].

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 14, Issue 1, Y-ECCO

30April2019

Y-ECCO Literature Review Introduction

Mark Samaan, Y-ECCO Literature Review Admin

Mark Samaan 2019
Mark Samaan 
© ECCO

 

Dear Y-ECCO Friends,

A warm welcome to the Y-ECCO Literature Review section, where you will find a summary and discussion of cutting-edge clinical trials as well as basic science studies in the field of IBD. 

If you are a Y-ECCO Member and you are looking for an opportunity to get actively involved in ECCO and gain some visibility, contribute your article to the Y-ECCO Literature Review corner, together with a short self-description and your picture.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 14, Issue 1, Y-ECCO

30April2019

Report on the 11th Y-ECCO Career Workshop at ECCO'19

Johan Burisch, Y-ECCO Member

Johan BurischJohan Burisch
© ECCO

Every two years, Y-ECCO arranges a workshop addressing topics about career and skill development for young researchers and physicians. We thereby aim to address important topics that are not fully covered during the rest of the ECCO Congress. This year the workshop took place for the 11th time, with the overall topic being modern career-enhancing skills. 

Posted in ECCO News, Volume 14, Issue 1, ECCO'19, Committee News, Congress News, Y-ECCO